Magnesium Bisglycinate in Major Depressive Disorder

Inclusion Criteria: 1. Patients with a diagnosis of Major Depressive Disorder (MDD) as per DSM-5 criteria. 2. Patients of either sex within the age group of 18-65 years. 3. Mild to severe depression, defined as a baseline MADRS score ≥7. 4. Currently receiving a stable dose of antidepressant monotherapy (SSRI or SNRI) in equivalent doses. 5. Willing and able to provide written informed consent. Exclusion Criteria: 1. Known hypersensitivity or allergy to magnesium supplements or glycine. 2. History of renal impairment (previous history of AKI, CKD, currently on dialysis). 3. Diagnosis of bipolar affective disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder. 4. Active suicidal ideation with intent or a recent suicide attempt (within the past 6 months), as assessed by the treating psychiatrist. 5. Current substance use disorder (except nicotine, alcohol and caffeine), as per DSM-5 criteria. 6. Pregnancy, lactation, or women of childbearing potential not using adequate contraception. 7. Concurrent use of magnesium-containing supplements, antacids, or laxatives. 8. History of significant severe medical comorbidity, including uncontrolled hypothyroidism, Cushing's syndrome, active malignancy, myasthenia gravis, or severe hepatic impairment. 9. Use of medications with significant pharmacokinetic interactions with magnesium (e.g., tetracyclines, fluoroquinolones, bisphosphonates, diuretics) that cannot be temporally separated by ≥2 hours. 10. Electroconvulsive therapy (ECT) received within the past 3 months.